Adamax

Key points

• Adamax is a brand style name for a blend, usually CJC-1295 with DAC, ipamorelin and BPC-157 in one vial.
• The first two are growth hormone peptides; BPC-157 is studied for tissue repair.
• Selling several unlicensed peptides together does not change their status.
• None of the components is licensed in the UK, and some are prohibited in sport.

Quick facts

What it is

Blend, usually CJC-1295, ipamorelin and BPC-157

Marketed for

Growth hormone support and recovery

UK status

Not a licensed medicine; sold for research use

Components

Each is unlicensed; some prohibited in sport

How it works

The blend combines a GHRH analogue (CJC-1295) and a growth hormone secretagogue (ipamorelin), which together prompt a pulse of growth hormone, with BPC-157, which is studied for tissue repair. Each component is covered in its own entry, where the evidence and limits are set out.

What the evidence shows

There is no evidence for Adamax as a specific product. The components have limited human evidence individually, and there are no controlled trials of this combination.

What it does not settle

• There are no trials of this blend as sold.
• The exact contents and ratios of a given vial are uncertain.
• Long term safety of the combination is unknown.

Side effects

Less common but serious

• The risks are those of the individual components, with the added uncertainty of what a blended product actually contains.
• Because there is no licensed product, the dose, purity and contents of material bought online cannot be verified.

Report any suspected side effect through the MHRA Yellow Card scheme.

UK legal status and access

Adamax has no UK marketing authorisation, so it is not a licensed medicine and is not offered by registered clinics or pharmacies. It is sold online as a research chemical.

Common questions